REGN vs TEM · P/E 14, rev $14.34B vs rev $693.4M
Regeneron Pharmaceuticals Inc (REGN) versus Tempus AI, Inc. Class A Common Stock (TEM) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Tempus AI, Inc. Class A Common Stock (TEM) is a health information services company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported TEM revenue for 2024-12-31 was $693.4M. Net income was -$705.8M. Revenue was up 30.4% from 2023-12-31 to 2024-12-31. TEM currently screens at market cap $8.76B.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TEM currently screens at market cap $8.76B.
Not investment advice. Open the REGN and TEM stock pages for the full models.
Not investment advice.